$18.30
1.93% yesterday
Nasdaq, Apr 02, 10:00 pm CET
ISIN
CH1242303498
Symbol
OCS
Sector
Industry

Oculis Stock price

$18.30
-1.24 6.35% 1M
+6.10 50.00% 6M
+1.30 7.65% YTD
+7.29 66.21% 1Y
+8.14 80.12% 3Y
+8.14 80.12% 5Y
+8.14 80.12% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.36 1.93%
ISIN
CH1242303498
Symbol
OCS
Sector
Industry

Key metrics

Market capitalization $878.40m
Enterprise Value $770.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 9.87
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-83.76m
Free Cash Flow (TTM) Free Cash Flow $-53.44m
Cash position $108.87m
EPS (TTM) EPS $-2.39
P/E forward negative
P/S forward 766.76
EV/Sales forward 672.87
Short interest 0.09%
Show more

Is Oculis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Oculis Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Oculis forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Oculis forecast:

Buy
100%

Financial data from Oculis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.46 0.46
-
-
-0.46 -0.46
-
-
- Selling and Administrative Expenses 24 24
-
-
- Research and Development Expense 59 59
-
-
-83 -83
-
-
- Depreciation and Amortization 0.46 0.46
-
-
EBIT (Operating Income) EBIT -84 -84
-
-
Net Profit -97 -97
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Oculis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oculis Stock News

Neutral
GlobeNewsWire
2 days ago
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET a...
Neutral
GlobeNewsWire
2 days ago
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from  10:00 AM to 12:00PM ET ...
Neutral
GlobeNewsWire
13 days ago
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.
More Oculis News

Company Profile

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Riad Sherif
Employees 49
Founded 2016
Website oculis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today